Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, Morel P, Mentha G, Combescure C.
Hepatology. 2012 Jan 23. doi: 10.1002/hep.25603. [Epub ahead of print]
Related citations
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients.
Levitsky J, Mathew JM, Abecassis M, Tambur A, Leventhal J, Chandrasekaran D, Herrera N, Al-Saden P, Gallon L, Abdul-Nabi A, Yang GY, Kurian SM, Salomon DR, Miller J.
Hepatology. 2012 Jan 11. doi: 10.1002/hep.25579. [Epub ahead of print]
Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database.
Singal AK, Bashar H, Anand BS, Jampana SC, Singal V, Kuo YF.
Hepatology. 2012 May;55(5):1398-405. doi: 10.1002/hep.25544. Epub 2012 Mar 18.
Circulating microRNAs as potential markers of human drug-induced liver injury.
Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG, Antoine DJ, French NS, Dhaun N, Webb DJ, Costello EM, Neoptolemos JP, Moggs J, Goldring CE, Park BK.
Hepatology. 2011 Nov;54(5):1767-76. doi: 10.1002/hep.24538.
Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial.
Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS; HALT-C Trial Group.
Hepatology. 2011 Nov;54(5):1527-37. doi: 10.1002/hep.24550.
Liver infarction after transjugular intrahepatic portosystemic shunt in a liver transplant recipient.
Wang MY, Potosky DR, Khurana S.
Hepatology. 2011 Nov;54(5):1887-8. doi: 10.1002/hep.24672. No abstract available.
Serum ferritin concentration and transferrin saturation before liver transplantation predict decreased long-term recipient survival.
Weismüller TJ, Kirchner GI, Scherer MN, Negm AA, Schnitzbauer AA, Lehner F, Klempnauer J, Schlitt HJ, Manns MP, Strassburg CP.
Hepatology. 2011 Dec;54(6):2114-24. doi: 10.1002/hep.24635.
Patatin-like phospholipase domain containing-3 Ile148Met and fibrosis progression after liver transplantation.
Valenti L, Fargion S.
Hepatology. 2011 Oct;54(4):1484. doi: 10.1002/hep.24601. No abstract available.
Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption.
Staufer K, Andresen H, Vettorazzi E, Tobias N, Nashan B, Sterneck M.
Hepatology. 2011 Nov;54(5):1640-9. doi: 10.1002/hep.24596.
Benefit of living donor liver transplantation: who and when?
Heimbach JK, Wiesner RH.
Hepatology. 2011 Oct;54(4):1125-6. doi: 10.1002/hep.24578. No abstract available.
The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C.
do O NT, Eurich D, Trautwein C, Neuhaus P, Neumann UP, Wasmuth HE.
Hepatology. 2011 Oct;54(4):1483-4. doi: 10.1002/hep.24535. Epub 2011 Aug 19. No abstract available.
Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail.
Charlton M.
Hepatology. 2011 Jul;54(1):3-5. doi: 10.1002/hep.24470. No abstract available.
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.
Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X.
Hepatology. 2011 Jul;54(1):20-7. doi: 10.1002/hep.24443.
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS Jr, Baker TB, Everson GT, Hong JC, Terrault N, Hayashi PH, Fisher RA, Everhart JE.
Hepatology. 2011 Oct;54(4):1313-21. doi: 10.1002/hep.24494.
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.
Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, Day CP, George J.
Hepatology. 2011 Oct;54(4):1208-16. doi: 10.1002/hep.24491. Epub 2011 Aug 9.
Raised sympathetic activity and blood ammonia could increase sensitivity to infections in patients with cirrhosis and refractory ascites who are using beta-blockers.
Kalambokis GN, Tsianos EV.
Hepatology. 2011 Oct;54(4):1486-7. doi: 10.1002/hep.24439. Epub 2011 Jul 21. No abstract available.
Does the donor mannose-binding lectin genotype really predict the risk of bacterial infections after liver transplantation?
Curvelo LA, de Mare-Bredemeijer E, de Canck I, van Thielen M, Kazemier G, Metselaar H, Kwekkeboom J.
Hepatology. 2011 May;53(5):1786-7. doi: 10.1002/hep.24114. No abstract available.
The impact of human immunodeficiency virus infection in liver transplantation for hepatocellular carcinoma.
Di Benedetto F, Tarantino G, Montalti R, D'Amico G, Cocchi S, Gerunda GE.
Hepatology. 2011 May;53(5):1777-8; author reply 1778-9. doi: 10.1002/hep.24235. No abstract available.
Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation.
Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, Ichai P, Saliba F, Adam R, Castaing D, Azoulay D.
Hepatology. 2011 May;53(5):1570-9. doi: 10.1002/hep.24231.
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men.
Lai JC, Verna EC, Brown RS Jr, O'Leary JG, Trotter JF, Forman LM, Duman JD, Foster RG, Stravitz RT, Terrault NA; Consortium to Study Health Outcomes in HCV Liver Transplant Recipients (CRUSH-C).
Hepatology. 2011 Aug;54(2):418-24. doi: 10.1002/hep.24390. Epub 2011 Jun 23.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on